€9m EU-project on Deep-Sea Organisms Started
News Feb 15, 2013
The collaborative project PharmaSea will bring European researchers to some of the deepest, coldest and hottest places on the planet. Scientists from the UK, Belgium, Norway, Spain, Ireland, Germany, Italy, Switzerland and Denmark will work together to collect and screen samples of mud and sediment from huge, previously untapped, oceanic trenches. The large-scale, four-year project is backed by more than €9.5 million of EU funding and brings together 24 partners from 14 countries from industry, academia and non-profit organisations.
The PharmaSea project focuses on biodiscovery research and the development and commercialisation of new bioactive compounds from marine organisms, including deep-sea sponges and bacteria, to evaluate their potential as novel drug leads or ingredients for nutrition or cosmetic applications. The international team of scientists is led by Professor Marcel Jaspars of the University of Aberdeen in Scotland, and coordinated by Dr. Camila Esguerra of the University of Leuven in Belgium.
One of the aims of PharmaSea is to discover new marine bacteria that can produce novel antibiotics: "There’s a real lack of good antibiotics in development at the moment. There hasn’t been a completely new antibiotic registered since 2003. If nothing’s done to combat this problem we’re going to be back to a ‘pre-antibiotic-era’ in around ten or twenty years, where bugs and infections that are currently quite simple to treat could be fatal", says Marcel Jaspars, who is Professor of Chemistry and Director of the Marine Biodiscovery Centre at the University of Aberdeen. PharmaSea will also focus on drug discovery for neurological, inflammatory, and other infectious diseases.
Only a handful of samples have ever been taken from deep trenches and investigated, so the project is breaking new ground. "PharmaSea will not only be exploring new territory at the bottom of the oceans, but also new areas in ‘chemical space’. With our broad platform of cutting-edge bioassays to detect drug-like activity, we'll be testing many unique chemical compounds from these marine samples that have literally never seen the light of day. We're quite hopeful that we'll find a number of exciting new drug leads", says Dr. Camila Esguerra, Industrial Research Fellow and Lecturer with the Laboratory for Molecular Biodiscovery at the University of Leuven.
The international team will employ strategies commonly used in the salvage industry to carry out the sampling. Using fishing vessels, researchers will drop a sampler on a reel of cables to the trench bed to collect sediment. Scientists will then attempt to grow unique bacteria and fungi from the sediment that can be extracted to isolate novel drug-like molecules for pharmacological testing. Partners from China, Chile, Costa Rica, New Zealand and South Africa will support the PharmaSea project. The first field tests will be carried out next autumn in the Atacama Trench in the Eastern Pacific Ocean, about 100 miles off the coast of Chile and Peru. The team will also search the Arctic waters off Norway and the Antarctic via Italian and South African partners. Deep trenches will also be accessed off New Zealand and China.
Marine organisms that live more than 6,000 meters below the sea level are considered to be an interesting source of novel bioactive compounds as they survive under extreme conditions. "Trenches are separated from each other and represent islands of diversity. They are not connected to each other and life has evolved differently in each one", explains Marcel Jaspars.
• University of Leuven (Belgium)
• The University of Aberdeen (UK)
• Aquapharm Biodiscovery Ltd (UK)
• University of Tromsø (Norway)
• eCoast Research Centre (Belgium)
• Biobridge Ltd (UK)
• Fundación MEDINA (Spain)
• University College Cork, National University of Ireland
• BIOCOM AG (Germany)
• Stazione Zoologica Anton Dohrn (Italy)
• Consiglio Nazionale delle Ricerche ibp-cnr (Italy)
• University of Santiago de Compostela (Spain)
• The Royal Society of Chemistry (UK)
• c-LEcta GmbH (Germany)
• Technical University of Denmark
• Deep Tek Ltd (UK)
• Advanced Chemistry Development UK Ltd
• Wuhan University (China)
• Institute of Microbiology – Chinese Academy of Sciences (China)
• University of the Western Cape (South Africa)
• Institute for Cell Dynamics and Biotechnology (Chile)
• National Biodiversity Institute of Costa Rica
• International Union for Conservation of Nature (Switzerland)
• University of Waikato (New Zealand)
Abzena Selects Sartorius Stedim Biotech to Equip its US Based Development and Manufacturing SitesNews
Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has selected Sartorius Stedim Biotech as its preferred equipment supplier in the U.S.READ MORE
Molecule Prevents Common Cold Virus from Hijacking Human CellsNews
Researchers have lab-tested a molecule that can combat the common cold virus by preventing it from hijacking human cells.READ MORE
Improving Pharmaceuticals: Catalyst Specifically Tuned to Integrate Fluorine AtomsNews
In the race to create more potent and stable medicines, scientists know that adding fluorine can improve drug molecules. However, there is only one fluorination reaction known to occur in nature which is performed by complex and highly specialized enzymes that are difficult to replicate. Now, scientists have developed a new, streamlined molecule that can do the work of enzymes but be designed and controlled minutely.READ MORE
Comments | 0 ADD COMMENT
World Congress on Bio-organic and Medicinal Chemistry
Nov 12 - Nov 13, 2018